Therapeutic area intelligence for Major Depressive Disorder with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Companies: 1

Companies

NBI-1065845 →

Assets

Neurocrine →

Recent signals(1)

ClinicalJune 24, 2026

Neurocrine's NBI-1065845 Shows Promise as Adjunctive Treatment for Major Depressive Disorder

A study is underway to assess the efficacy and safety of NBI-1065845 as an adjunctive treatment for Major Depressive Disorder.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Major Depressive Disorder →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.